
New production area
📣 We are excited to announce the launch of a new production area designed for the synthesis of highly potent Active Pharmaceutical Ingredients (HPAPIs). This expansion proves our commitment to providing specialized solutions for the development and manufacturing of life-saving medications. Our focus within this new facility will be the production of ifosfamide 💊 CEP (Certificate of Suitability) for ifosfamide has already been granted to TZF Polfa. We are diligently working towards achieving EU…

TZF Polfa is highly active on the international stage
TZF Polfa is highly active on the international stage, and we’re excited to offer another product to our customers. Additionally, we’re pleased to produce active pharmaceutical ingredients in Poland, aligning with current trends of reducing reliance on suppliers outside of Europe 💊 The ability to offer Ifosfamide aligns with our plans for manufacturing high-potent products at Polfa – said Marta Moszkowicz. We look forward to sharing further updates on our progress in the coming months…

Discover our advanced analytical and preformulation services! 💊
We take pride in our advanced capabilities in analytical, preformulation and our specialty, reverse engineering studies, designed to add significant value to your products and development activities. Our key services include, among others 👇 🔬 Preformulation, analytical, reverse engineering studies: ▪️ Active Pharmaceutical Ingredient (API) characterization, ▪️ Morphology and particle size analysis (PSD), ▪️ Morphology and…

Information brochure – production plant
We are lunching second stage of investment in the modern oncological and immunosuppressive pharmaceuticals plant. The building will include a laboratory area for quality control, dedicated to product testing and a laboratory area for the R&D department. Apart from the production and laboratory area, the building will house sanitary and social facilities, office and technical rooms. TZF Polfa plans to implement the investment described in Information Letter No. 2/2021. by two General Contractors, selected …

The New Production Department of Sterile Forms “Ampoule Facility”
Polfa Tarchomin offers the possibility of manufacturing sterile medicinal products in the form of solutions based on water and / or organic solvents in ampoules in the new Production Department of Sterile Forms which starts operating this year:
- 2ml and 5ml ampoules
- maximum batch size up to 250 liters
- capacity of the dosing line 18,000 / hour
- sterile filtration on sterile filters or final sterilization of the product
- tightness testing and visual inspection of ampoules
- technological process carried out in purity classes:

TZF on the CPhI
On 04th-07th of November, TZF will take a part in the world’s largest pharmaceutical event – CPHI, which year by year have hosted more than 45 000 industry experts. Our team of experts will be delighted to provide you insights about the company and possible cooperation area, such as FDF and API portfolio availability for out-licensing & distribution or Contract Manufacturing. Hall 9.1, zone FDF, stand: 91H80, Frankfurt Messe.
- Core of our production:
- Prescritpion drugs (Anfi-infection for systematic use, Alimentary